Abstract
Estrogen aids in neo-vascularization of various tumors during hypoxic conditions, however the role of estrogen within the hypoxic environment of thyroid cancer is not known. In a series of experimentations, using human thyroid cancer cells, we observed that estrogen and hypoxia modulate the hypoxia inducible factor-1 (HIF-1) signaling which is abrogated by the anti-estrogen fulvestrant and the HIF-1 inhibitor YC-1 (3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole). Furthermore, we found that the conditioned medium from estrogen treated thyroid cancer cells lead to enhanced migration and tubulogenesis of human umbilical vein endothelial cells (HUVECs) which is abrogated by HIF-1 inhibitor. These findings, in addition to our previous and other scientific literature data, lead us to conclude that estrogen and hypoxia are interlinked in thyroid cancer and can equally modulate epithelial-endothelial cell interactions by mediating key cellular, metabolic and molecular processes of thyroid cancer progression. We believe that the hormonal component and cellular adaptation to oxygen tension of cancer cells are functionally equivalent with a cellular transition that can be exploited clinically for a combinational approach for thyroid cancer treatment involving antiestrogens as well as anti-hypoxic agents.
Keywords: Angiogenesis, antiestrogens, estrogen, human umbilical vein endothelial cells, hypoxia, hypoxia inhibitors, thyroid cancer.
Current Medicinal Chemistry
Title:Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Volume: 21 Issue: 11
Author(s): S. Rajoria, E. Hanly, A. Nicolini, A.L. George, J. Geliebter, E.J. Shin, R. Suriano, A. Carpi and R.K. Tiwari
Affiliation:
Keywords: Angiogenesis, antiestrogens, estrogen, human umbilical vein endothelial cells, hypoxia, hypoxia inhibitors, thyroid cancer.
Abstract: Estrogen aids in neo-vascularization of various tumors during hypoxic conditions, however the role of estrogen within the hypoxic environment of thyroid cancer is not known. In a series of experimentations, using human thyroid cancer cells, we observed that estrogen and hypoxia modulate the hypoxia inducible factor-1 (HIF-1) signaling which is abrogated by the anti-estrogen fulvestrant and the HIF-1 inhibitor YC-1 (3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole). Furthermore, we found that the conditioned medium from estrogen treated thyroid cancer cells lead to enhanced migration and tubulogenesis of human umbilical vein endothelial cells (HUVECs) which is abrogated by HIF-1 inhibitor. These findings, in addition to our previous and other scientific literature data, lead us to conclude that estrogen and hypoxia are interlinked in thyroid cancer and can equally modulate epithelial-endothelial cell interactions by mediating key cellular, metabolic and molecular processes of thyroid cancer progression. We believe that the hormonal component and cellular adaptation to oxygen tension of cancer cells are functionally equivalent with a cellular transition that can be exploited clinically for a combinational approach for thyroid cancer treatment involving antiestrogens as well as anti-hypoxic agents.
Export Options
About this article
Cite this article as:
Rajoria S., Hanly E., Nicolini A., George A.L., Geliebter J., Shin E.J., Suriano R., Carpi A. and Tiwari R.K., Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression, Current Medicinal Chemistry 2014; 21 (11) . https://dx.doi.org/10.2174/0929867321666131201142434
DOI https://dx.doi.org/10.2174/0929867321666131201142434 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design The Genetics and Genomics of Systemic Sclerosis: An Update and Review
Current Rheumatology Reviews From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Difference Gel Electrophoresis: Application in Quantitative Proteomics Research
Current Proteomics Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science A Case Analysis on CT Guided Percutaneous Lung Puncture Biopsy of Lymphocyte Mesenchymal Pneumonia
Combinatorial Chemistry & High Throughput Screening The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology Using Fragment-Based Technologies to Target Protein-Protein Interactions
Current Pharmaceutical Design Editorial [Hot topic: Role of Apoptosis in Chemotherapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Drug Targets APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism Use of Mouse Models to Evaluate Roles of Nuclear Receptors and their Ligands in the Pathogenesis and Treatment of Atherosclerosis
Current Drug Targets Identifying the Characteristics of the Hypusination Sites Using SMOTE and SVM Algorithm with Feature Selection
Current Proteomics MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets A Review on the Use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis
Current Drug Targets Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry